Nectome is fantastic! The crosslinking approach made sense to me the second Aurelia explained it to me last year. Better preservation through better chemistry. And even with the 12 minute window, I know they are actively developing systems to make that operationally doable in real world settings.
My question is about the policy and adoption side. Aurelia mentions the end goal of making this part of standard end-of-life care, even Medicare. What does the lobbying and regulatory strategy actually look like right now? Who are the key stakeholders you are working with, and where do you see the most tractable near-term wins: state by state MAiD expansion, insurer conversations, medical establishment buy-in?
Nectome is fantastic! The crosslinking approach made sense to me the second Aurelia explained it to me last year. Better preservation through better chemistry. And even with the 12 minute window, I know they are actively developing systems to make that operationally doable in real world settings.
My question is about the policy and adoption side. Aurelia mentions the end goal of making this part of standard end-of-life care, even Medicare. What does the lobbying and regulatory strategy actually look like right now? Who are the key stakeholders you are working with, and where do you see the most tractable near-term wins: state by state MAiD expansion, insurer conversations, medical establishment buy-in?